Clean Yield Group Boosts Holdings in Danaher Co. (NYSE:DHR)

Clean Yield Group grew its holdings in Danaher Co. (NYSE:DHR) by 26.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 932 shares of the conglomerate’s stock after acquiring an additional 197 shares during the period. Clean Yield Group’s holdings in Danaher were worth $214,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also modified their holdings of the company. Teachers Insurance & Annuity Association of America purchased a new stake in Danaher during the 3rd quarter worth about $39,000. MidAtlantic Capital Management Inc. purchased a new stake in shares of Danaher during the third quarter worth approximately $40,000. FSA Wealth Management LLC acquired a new stake in Danaher in the third quarter valued at approximately $50,000. Darwin Wealth Management LLC purchased a new position in Danaher in the third quarter worth approximately $55,000. Finally, Modus Advisors LLC acquired a new position in Danaher during the 4th quarter worth approximately $56,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Trading Up 1.7 %

Shares of DHR stock traded up $4.03 during mid-day trading on Monday, hitting $239.10. 2,071,626 shares of the company’s stock were exchanged, compared to its average volume of 2,739,586. The stock has a market cap of $172.70 billion, a price-to-earnings ratio of 45.63, a PEG ratio of 4.32 and a beta of 0.83. The stock has a 50-day simple moving average of $235.67 and a two-hundred day simple moving average of $253.73. Danaher Co. has a fifty-two week low of $222.53 and a fifty-two week high of $281.70. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The company had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same quarter in the prior year, the company posted $2.02 EPS. The company’s quarterly revenue was up 3.1% compared to the same quarter last year. Equities analysts expect that Danaher Co. will post 7.5 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be given a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.45%. The ex-dividend date of this dividend is Friday, December 27th. Danaher’s dividend payout ratio (DPR) is presently 20.61%.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on DHR. Wolfe Research raised Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price objective for the company in a research report on Thursday, October 31st. Scotiabank initiated coverage on shares of Danaher in a research report on Monday, December 23rd. They set a “sector perform” rating and a $265.00 target price on the stock. Stephens reiterated an “overweight” rating and issued a $315.00 price target on shares of Danaher in a research report on Wednesday, October 23rd. KeyCorp raised their price objective on shares of Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 23rd. Finally, Citigroup reduced their target price on shares of Danaher from $305.00 to $285.00 and set a “buy” rating for the company in a report on Monday, January 6th. Six equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, Danaher presently has an average rating of “Moderate Buy” and an average price target of $286.80.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.